CEO Aikawa Chairs Symposium and Five Doctors Present Research Findings, Promoting Academic Exchange for the Advancement of Aesthetic Medicine
IRVINE, Calif. -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical" or the "Company"), a Medical Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced that Dr. Yoshiyuki Aikawa, CEO of the Company and Founder of Shonan Beauty Clinic, who also serves as a board member of the Japan Society of Aesthetic Surgery (JSAS), served as a symposium chair at "The 114th Congress of the Japan Society of Aesthetic Surgery" held over two days from May 28, 2026, at The Okura Tokyo. Additionally, five physicians from the clinic network supported by SBC Medical presented their latest research findings at the congress.
The Japan Society of Aesthetic Surgery (JSAS) is one of Japan's leading professional societies where physicians engaged in aesthetic healthcare refine their skills and share the latest insights. The 114th Congress was held under the theme "Connecting Beauty, Unlocking the Future, Tradition Meets Innovation from Japan," where active discussions took place regarding international trends and future prospects in aesthetic healthcare. It provided a valuable opportunity for specialists in various fields to deepen their academic and clinical knowledge and to promote global collaboration.
Dr. Yoshiyuki Aikawa, serving as a board member of the society, chaired a symposium at the congress, leading discussions on the future of aesthetic healthcare from a management perspective, focusing on the integration of medical care, marketing, customer management, and AI technology. Furthermore, five physicians from the clinic network supported by SBC Medical spoke and presented their research findings across various formats, including symposia, general sessions, video sessions, and luncheon seminars. The presentations covered a wide range of fields, from foundational to cutting-edge topics, sharing insights gained through daily clinical practice and research.
As technological innovation continues to accelerate in the field of aesthetic healthcare, the importance of knowledge sharing and academic collaboration, beyond the clinical setting alone, has grown considerably. Meeting the increasingly diverse needs of customers requires not only the adoption of advanced techniques, but also broad perspectives and flexible thinking. SBC Medical remains committed to advancing cutting-edge initiatives through academic presentations and research collaborations, and to upholding the safety, transparency, and enduring value of aesthetic healthcare.
Overview of "The 114th Congress of the Japan Society of Aesthetic Surgery"
Venue: The Okura Tokyo (Toranomon)
Dates: May 28, 2026 – May 29, 2026
Official Website: https://square.umin.ac.jp/jsas114/index.html
List of Presentation Topics
[Symposium (Chair)] Yoshiyuki Aikawa, CEO (SBC Medical Group Holdings
Incorporated)
Redefining Medical Excellence at the Intersection of Marketing, Management, and AI ～From Clinical Expertise to Sustainable Excelle～
[Symposium (Speakers)] Dr. Keiichiro Kasai (Director, Shonan AGA Clinic Shinjuku Southern Terrace)
Hair Regeneration and Anti-Aging：Current Strategies and Future Perspectives
Dr. Soichiro Morikawa (Director, NEO Skin Clinic Ginza)
Combination Strategies and Treatment Sequence for Devices and Injections in Skin Rejuvenation Therapy
[Video Session] Dr. Daisuke Sato (Vice Director, Ritz Cosmetic Surgery Tokyo)
My Approach to Sub-SMAS Dissection in Facelift Surgery
[General Presentations] Dr. Shunsuke Nagura (Director, Shonan Beauty Clinic Akihabara)
Efficacy of Acellular Dermal Matrix for Correction of the Alar Base Paranasal Hollow：A Clinical Study of 50 Asian Patients
Dr. Atsushi Hayashi (Director, Shonan Beauty Dermatology Clinic Gotanda)
Adverse Events Associated with Different Amounts of Botulinum Toxin Injection into the Cheek Dermis for Skin Quality Improvement
[Luncheon Seminar] Dr. Soichiro Morikawa (Director, NEO Skin Clinic Ginza)
Clinical Application of Polynucleotide Injectables：Current Evidence and Emerging Approaches
About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose "Contributing to the well-being of people around the world through medical innovation," SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com
For more insights and updates from SBC Medical, follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," "targets" or "hopes" or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading "Risk Factors" and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), which are accessible on the SEC's website at www.sec.gov.
Contacts
Hikaru Fukui / Head of IR Department; E-mail: ir@sbc-holdings.com
Akiko Wakiyama / Chief Public Relations Officer; E-mail: pr@sbc.or.jp